Search results
Author(s):
Andreas Metzner
,
Erik Wissner
,
Tina Lin
,
et al
Added:
3 years ago
Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting 1.5–2 % of the general population.1 In the current clinical guidelines, catheter ablation is recommended in addition to drug-based antiarrhythmic therapy for patients suffering from symptomatic, drugrefractory AF. However, catheter ablation, if performed at an experienced centre, may also serve as first-line therapy in…
View more
Author(s):
David Schaack
,
Boris Schmidt
,
Shota Tohoku
,
et al
Added:
11 months ago
Author(s):
Axel Brandes
,
Marcelle D Smit
,
Bao Oanh Nguyen
,
et al
Added:
3 years ago
Atrial fibrillation (AF) is the most common clinical arrhythmia worldwide and is expected to increase in the coming decades.1,2 It currently affects up to 3 % of Western populations aged 20 years or older, and the number of affected individuals in the EU will increase from about 7 million to almost 13 million by 2030.3–5 This growing epidemic is not only caused by the natural ageing of the…
View more
Author(s):
Dario DiFrancesco
Added:
3 years ago
HCN4 (hyperpolarisation-activated, cyclic nucleotide gated 4) channels, the pore-forming α–subunits of ‘funny’ channels originally described in pacemaker cells of the sinoatrial node (SAN),1 are responsible for the early phase of diastolic depolarisation in these cells and are key determinants of pacemaker generation and control of heart rate.2–5 HCN4 channels are selectively expressed in the SAN…
View more
Author(s):
Boris Schmidt
,
Tom De Potter
,
Added:
2 years ago
In this video from Arrhythmia Academy's Journal Club, Dr Tom De Potter (Cardiovascular Center, OLV Hospital, BE) is joined by Prof David Duncker (Hannover Heart Rhythm Center, Hannover, DE) and Dr Boris Schmidt (Cardioangiologisches Centrum Bethanien, Frankfurt, DE) to discuss the latest technological developments in the ablation of atrial fibrillation. Dr De Potter presents the latest…
View more
Author(s):
Francisco Lopez-Jimenez
,
David M Harmon
Added:
10 months ago
In this episode from the Radcliffe Podcast, Dr Francisco Lopez-Jimenez (Mayo Clinic, US) and Dr David Harmon (Mayo Clinic, US) join us to discuss the future of AI in Atrial Fibrillation treatment, based on Dr Harmon's recently published article in AER Journal; 'Artificial intelligence for the detection and treatment of atrial fibrillation'.
Dr Lopez-Jimenez and Dr Harmon discuss the…
View more
Author(s):
Junaid AB Zaman
,
Andrew Grace
,
Sanjiv M Narayan
Added:
1 year ago
Author(s):
Jonathan S Steinberg
Added:
4 years ago
HRS 2019: ERADICATE- Atrial Fibrillation Trial
View more
Author(s):
Stylianos Tzeis
Added:
2 years ago
In this video Dr Stylianos Tzeis explains the ideal treatment pathway for patients with heart failure and Atrial Fibrillation to optimise patient outcomes.
Key Learning Objectives:
How can atrial fibrillation and heart failure intersect and what should you treat first?
The ideal patient pathway for patients with both AF and heart failure
AF treatment outcomes to expect for patients with…
View more
Author(s):
Sanjiv M Narayan
,
David E Krummen
Added:
3 years ago
Atrial fibrillation (AF) is the most prevalent arrhythmia in the world and a leading cause of hospitalisation and death.1 Current therapy for AF remains suboptimal, in large part because its mechanisms are uncertain. However, recent advances in our understanding of human AF, from meticulous mapping in patients and insights from animal models, are providing new therapeutic options for patients.
…
View more